Aurobindo Pharma Limited — Board Meeting, 04-08-2025: Outcome of Board Meeting

Aurobindo Pharma's board has announced a meeting where it approved the financial results for the quarter ended June 30, 2025. The company's consolidated revenue from operations for the quarter stood at ₹7,791.77 Cr, with profit after tax at ₹824.20 Cr. The board also declared an interim dividend of ₹4.00 per equity share. Strategically, the company incorporated new step-down subsidiaries, CuraTeQ Biologics B.V. and Cresedemo Pharma LLC. Its US subsidiary also entered a definitive agreement to acquire 100% of Lannett Company LLC, pending approvals.